Jun 2, 2025 - Business

Sanofi buying Blueprint Medicines for up to $9.5 billion

Illustration of a blueprint drawing of an uncompleted hundred dollar bill — Illustration: Aïda Amer/Axios

Sanofi agreed to acquire Blueprint Medicines, a Cambridge, Mass.-based biotech focused on rare immunology diseases, for $9.1 billion in cash and up to $400 million in earnouts.

Why it matters: This is Sanofi's third big buy in 2025, following Dren Bo and Vigil Neuroscience, as it tries to build up a portfolio that's become too reliant on its Dupixent anti-inflammatory drug.

The situation that's been exacerbated by some recent clinical setbacks and the April sale of a control stake in its consumer health unit to Clayton Dubilier & Rice for €10 billion.

By the numbers: Blueprint stockholders are slated to receive $129 per share at closing, representing a 23.3% premium over Friday's closing price.

They'd also get contingent value rights that could include up to $6 in milestone payments.

The bottom line: Sanofi's rare disease expertise could significantly boost the market penetration of Blueprint's systemic mastocytosis drug Ayvakit, which generated about $150 million in Q1 sales.

Add Axios on Google

Sanofi buying Blueprint Medicines for up to $9.5 billion

What to read next